Company intelligence / Profile preview
OncoSynergy
Stamford, Connecticut, United Statesoncosynergy.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
OncoSynergy is developing OS2966, a first-in-class anti-CD29 monoclonal antibody that has received FDA Investigational New Drug approval and is advancing to Phase 1 clinical trials in recurrent glioblastoma. The therapeutic targets cancer's "achilles heel" by cutting off multiple biological processes simultaneously, addressing therapeutic resistance which is the number one cause of death in cancer patients[2][5].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on OncoSynergy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoSynergy.